The inclusion of lactate dehydrogenase and the resulting lactic acidosis play a role in the transformation of solid hypoxic cancers into metastatic tumour's.

Lactate acidosis is a feature shared by solid hypoxic cancerous tumours, including those that develop in the breast, colon, and prostate. Even though extreme lactate acidosis is damaging to healthy cells, malignant tumours actually benefit from it in a number of different ways. Lactate is utilized by tumour cells as a means of promoting their development, resisting the effects of chemotherapy, and increasing their ability to evade the immune system. Hypoxic cancer cells, which lack oxygen, have the potential to learn the most aggressive behaviors thanks to the benefits of lactic acidosis. Because aggressive hypoxic cancer cells have a high chance of metastasizing to other organs, it is difficult to manage a tumour at this stage with chemotherapy due to the fact that it can be a challenge. Stopping hypoxia-induced lactate dehydrogenase from working can prevent cancers from behaving in an aggressive manner. In this article, we will investigate how hypoxia-induced lactic acidosis leads to the aggressive transformation of malignant cells. This review also offers fresh perspectives on the variety of LDH isoforms as well as the inhibitors that specifically target those isoforms. 1. Introduction Lactate acidosis in the tumor microenvironment of solid tumor of mammary gland, prostate gland, colon cancer as well as in lung carcinoma is one of the most commonly observed altered metabolic feature 1 . Hypoxia (reduced level of oxygen) plays a pivotal role in this metabolic alteration. Hypoxia frequently develops in solid tumors when a tumor acquires reasonable size. Under hypoxic conditions, cancer cells oxidize glucose preferentially through glycolysis and this results in excessive secretion and accumulations of lactate in the tumor microenvironment. Several studies have documented this type of metabolic adaptation in hypoxic cancer cells 2,3 . It would be pertinent to mention here that metabolic acidosis due to lactate in tumor microenvironment is different from the acidity is a general. Acidity in general is referred to as systematic acidosis whereby H + ions are contributed by H 2 CO 3, Pentose phosphate pathway and other sources. While lactate acidosis is a specifically means H + ions contributed by lactic acid synthesized and secreted by hypoxic cancer cells in the tumor microenvironment as result of metabolic perturbations 4 . Previous studies have already reported that compared to general acidosis, lactate acidosis is more severe condition because it involves imbalance of a specific metabolite and associated with severe issues like shock or tissue hypoxia, and carries higher risk of mortality 5,6 . In this manuscript, authors main focus is on the lactate acidosis specifically present in the tumor microenvironment and to find the motive of cancer cells behind this adaptation. Cancer cells have only one motive behind this adoption i.e. metastatic transformation. Several studies have reported strong link between lactic acidosis and aggressive metastatic transformation of cancer cells and poor treatment outcomes 7 8 . Dr. Petr Heneberg investigated the tissue-specific effect of lactic acidosis on 57 patients with solid tumors. He observed that lactic acidosis results in a very bad treatment prognosis in individuals with solid tumors treated with chemotherapeutic agents due to lactate acidosis in the TME 9 .In addition, lactate acidosis interferes with immune cell activity in the TME. Lactate also induces pro-tumoral differentiation of M2-type macrophages, enhances their growth and existence, and thus impair with the anti-tumor immunity as well. A current work by Fischbeck et al. reported that lactic acidosis reduces the doings of T lymphocytes and natural killer (NK) cells 10 . In another study on breast cancer patients, they observed that some cancer cells changed their metabolic profile with the aim of shifting tumor cells to alternative energy sources 11 . Ishihara et al. also highlighted in their studies that tumor cells switch glucose metabolism from oxidative to glycolysis to yield more lactate to accomplish their needs 12 . They measured the quantity of ATP generated in the glycolysis process and OXPHOS in a randomly nominated tumor cell line in the presence or absence of lactate acidosis. Glycolysis generated 23% –52% of total ATP, and OXPHOS generated 48% – 76% of total ATP without lactic acidosis. In the company of lactate acidosis, glycolysis yielded 5.7% − 13.4% ATP, while OXPHOS generated 87 % − 94% of total ATP. They determined that the Warburg effect was reversed by lactic acidosis in OXPHOS cancer cells. They concluded that normoxic and hypoxic cancer cells in the TME develop a metabolic symbiosis in order to disperse the accumulated lactate as well as to support each other’s survival 12 . Cancer cells always have a motive behind them if found doing something unusual. Few of these studies have clearly documented the role of lactate in their survival. In this review author explained that how lactate in hypoxic cancer cells helping them in acquiring a metastatic behaviour. In the last section, author explained the inhibition of Lactate dehydrogenase is the best strategy curb metastatic transformation of cancer cells. 2. Lactate acidosis imparts resistance against chemotherapy Chemotherapeutic agents can be of natural or synthetic origin and are specially designed to kill rapidly proliferating cancer cells. Some chemotherapeutic agents such as cyclophosphamide, anthracycline, busulfan, thiotepa, tamoxifen, and vincristine work best in tumors with a very good supply of blood 1314 . Although chemotherapeutics are effective treatments for many different forms of cancer, they have failed to show efficacy in solid hypoxic tumors of mammary gland cancer, colorectal cancer, and prostate cancer due to changes in pH of the TME due to excessive secretion of lactate 15 . Various studies have reported the failed efficiency of anti-cancer agents due to changes pHe in the TME. Tord Hompland et al. reported that tumor cells reprogram the metabolism of glucose in order to increase the lactate acidosis which indirectly impar resistance to chemotherapy 13 . Qi Dong et al. also reported that non-small lung cancer cells reprogrammed glucose metabolism upon treatment with etoposide and subsequently increased lactate acidosis in TME. They noted under the influence of lactate acidosis, lung cancer cells enhanced expression of multidrug resistance-associated protein-1(MRP-1) which acts as an efflux pump in tumor cells 16 . In order to assess the impact of lactate acidosis on drug resistance, Emily M. E. Barnes et al. treated HCT 116 colon tumor cells and LS174T with Uprosertib both in its presence and absence of lactate acidosis. Uprosertib is a familiar anti-cancer medication that targets glycolysis by inhibiting the Akt pathway. They observed in their study that cancer cell lines (HCT 116 colon tumor cells and LS174T) started consuming lactate in glucose-deficient conditions and reported that this is one way to impart resistance against chemotherapy. Further, they treated cancer cells with MCT-1 inhibitors and Uprosertib both. This time they observed apoptosis in Uprosertib and MCT-1 inhibitor treated drugs. Based on these finding they reported that resistance to chemotherapeutics can be prevented by blocking lactate entry into cancer cells 17 . In another similar study conducted by Maria Apicella et al., reported that Tyrosine kinase inhibitors (TKIs) treated cancer cells developed the lactate acidosis by shifting their metabolism to glycolysis only. They observed under the influence of lactate acidosis cancer cells enhanced expression of Nuclear factor-κB (NF-κB) which indirectly enhanced the expression of Hepatocyte growth factor (HGF) by tumor-associated fibroblasts. Furthermore, increased HGF levels enhanced resistance to TKIs through MET-dependent signaling mechanisms in tumor cells. Also, In vivo, resistance was noted to eliminated with the reduction of lactate acidosis in the TME 18 . In another study, Junxing Qu and colleagues found that Candida tropicalis (C.tropicalis) increases resistance to oxaliplatin treatment in colon cancer cells by decreasing the level of Miss match repair (MMR) proteins. Based on the results, it was concluded that C. tropicalis increased the glucose uptake in cancer cells and subsequently increased lactate conferred resistance to the Oxaliplatin therapy 19 . Ruishuang et al. in their study of non-small cell lung cancer (NSCLC) cell lines - PC-9 and HCC827 also reported that lactate sustained viability in these cells lines and posed resistance to erlotinib therapy. Further they noted lactate binds on the GPR81 receptor and activated the AKT signalling pathway and finally enhanced cell viability. Silencing of GPR81 reduced AKT expression and thus increasesd apoptosis in erlotinib treated cells. Higher expression of GPR81 and MCT-1 both in lactate acidosis contributed significantly development of resistance 20 . The aforementioned discussion leads to the hypothesis that lactate diverse mechanisms to develop resistance against chemotherapeutics agents. Lactate can re-ennter the cancer cells and utilsed in oxidative phosphorylation and thus helps starving cancer cells. Apart from this, lactate induced the expression of NfkB which enhances the expression of HGF. Last but not the least, lactate can also bind to the GPR81 receptor, enhances intracellular cAMP buildup, and activates protein kinase A. PKA goes on to phosphorylate the protein p-CREB, which is a member of the leucine-zipper superfamily of transcription factors. Once triggered, pCREB moves into the nucleus and increases the production of DNA mismatch repair genes such as MLH1, which causes cancer cells to adapt by mutation. Cancer cells develop adaptive mutational traits can create a variety of defence mechanisms to combat chemotherapy-induced stress. Apart from this, lactate also helps the cancer cells in the process of neovascularization which is discussed in the next section. 3. Lactate acidosis enhances angiogenesis in hypoxic tumors Angiogenesis is the development of new blood vessels from already existing blood vessels. Various chemical factors regulate angiogenesis in the solid tumors 21 . Several factors like VEGF and growth factors like EGF promotes the cells division in endothelial cells. In solid hypoxic tumors HIF-1 αis well know for its role in angiogenesis but exact mechanism is still remains unexplored. Recent work has contributed a lot to understand the molecular mechanism exploited by the HIF-1α in regulation of angiogenesis. As per the literature, HIF-1α, change the metabolism of glucose, creating an acidic tumor microenvironment which then help in angiogenesis. Several studies have documented the role of lactate in angiogenesis 22 . Click or tap here to enter text. Vegran et al. reported that two lactate molecules can enter endothelial cells via MCT-1 and activate an autocrine pathway involving NF-κB and IL-8, which encourages cell migration and tube development, causing IκBα to be phosphorylated or degraded. Finally, they demonstrated that lactate discharge from cancer cells via the MCT4 transporter is adequate to initiate IL-8-dependent angiogenesis and tumor development in xenograft mouse models of human breast cancer and colorectal cancer. In conclusion, their research revealed that endothelial cells can use lactate to initiate angiogenesis 23 . Intracerebral hemorrhage (ICH) is associated with lactate accumulation in the brain. According to the finding of the Zhou et al., research, lactate induced the angiogenesis and neurogenesis in collagenase induced ICH rat model. They noted, exogenously administration lactate considerably increased the number of PCNA+/DCX+ cells and PCNA+/vWF+ nuclei. Fuurther, they observed under the influence lactate, promoted p65 translocation to the nucleus of neuronal cells and activated thus enhanced the expression of NF-κB, which led to a substantial elevation of mRNAs and proteins of basic fibroblast growth factor (bFGF )and VEGF in comparison in the brain tissue of experimental animals. These finding clearly stated that lactate plays pivoatal role in in angiogenesis and neurogenesis 24 . Dhup et al. reported in his research that HIF-1α induced lactate acidosis exerts several pro-angiogenic effects, including the promotion of endothelial cell migration, VEGF release by macrophages, vascular morphogenesis, and attraction of circulating vascular progenitor cells. Apart from this, lactate also contributed significantly to tissue healing by increasing collagen synthesis, production of Transforming growth factor-β (TGF-β), and fibroblast proliferation 25 . Hunt et al. also demonstrated in his review that lactate buildup frequently in tumor microenvironment of solid tumours stimulate synthesis and secretion of various interleuukins-1(IL-1) and growth factors like VEGF, transforming growth factor-beta (TGF β), and HIF-1α which eventually promotes angiogenesis in cancer cells. Further, it has been observed that increased monomeric concentrations of lactate in wounds forces the fibroblasts to produce collagen as well as it regulates the post transcriptional hydroxylation of collagen. Lactate also directs the macrophages to produce VEGF 26 . The above finding was further supported by Liu et al., research work which concluded that all the major by products of glycolysis like pyruvate, lactate and acetoacetate upsurge the level of HIF-1α even in the presence of oxygen in order to enhance the VEGF expression 27 . Pierre Sonveaux et. al, discovered that inhibiting lactate inflow into ECs can prevent HIF-1-dependent angiogenesis from occurring. Their hypothesis was supported by the first-ever analysis of lactate-induced HIF-1 stimulation in normoxic ECs and the subsequent rise in VEGFR2 and basic fibroblast growth factor (bFGF) expression. Further, they demonstrated that MCT1 inhibitors blocked the HIF-1α induced angiogenesis as evidenced by the results of cell migration assay and immunohistochemistry. The study highlights MCT1 inhibition as a treatment strategy to control angiogenesis in solid tumors, This, study also established a link between HIF-1α and Lactate 22 . From the above findings one can infer that lactate is a strong activator of angiogenesis. Lactate can cause angiogenesis in two separate ways. First, lactate enters the ECs cells through the MCT-1 transporter, which causes activation of cytoplasmic proteins like HIF-1 to become active. VEGFR and bFGFR are two genes that are transcriptionally induced by activated HIF-1, and these receptors subsequently receive signals for angiogenesis. Second, intracellularly built-up lactate activates the NfkB protein and the cytokine IL8, both of which aid in angiogenesis. Angiogenesis is followed by invasion. The role of lactate in invasiveness is discussed in the next section (Figure1). 4. Lactate acidosis enhances invasiveness in solid hypoxic tumors When a cancer cell detaches from its site of origin and penetrates the surrounding tissues, this behaviour of tumour cells is read as invasion. Invasiveness helps tumour cells develop secondary tumors in the nearby organs. Tumors with invasive properties are considered more aggressive. Once tumor cells acquire invasive behaviour, their management with chemotherapy becomes very difficult. Invasive cancer is associated with high mortality 28,29 . Alterations in the TME give tumor cells a clever proliferative advantage for invading the nearby normal tissue. Tumor acidity is a critical factor in local invasion and metastasis, as evidenced by several studies 30 . Extracellular acidification destroys normal tissues by triggering p53-dependent apoptotic pathways. It has been reported that a low extracellular pH (pHe) creates an ideal microenvironment for the activation of cathepsin B, D, and L proteases, matrix metalloproteinase s ( MMPs ), and urokinase-type plasminogen activators. For example, human MMP-3 has the highest level of activity within the ideal pH range of 5.75 and 6.25. One can speculate that an acidic TME stimulates the activation of proteolytic enzymes, such as cathepsin B, D, and L proteases, MMPs, and urokinase-type plasminogen activators, to initiate invasion of nearby organs 31 . A similar effect of lactate on invasiveness was also observed by Penningto et al. Reduced pHe stimulates proteinases produced by tumor cells, including hyaluronidase-2, cathepsin B, and MMP-enzymes, which damage the surrounding matrix and stimulate tumor cell invasion. Their inhibition greatly reduces tumor cell invasion in pre-clinical investigations. Growth factors contained in the ECM, such as VEGF, transforming growth factor (TGF), and fibroblast proliferation factor-2 (FGF2), may be released during ECM lysis by secreted proteinases, further promoting tumor invasiveness and growth. In vitro, acidification of the extracellular environment increases the manufacture of hyaluronan and tumor-specific forms of CD44, which bind hyaluronan and permit tumor cell invasion 32 . Izumi et al. reported that MCT1 also significantly contributes to tumor cell invasion. Overexpression of MCT-1 has been observed in In-vivo human lung cancer cell invasiveness and inhibitors of MCT-1 have significantly reduced the invasiveness. As MCT-1 is a lactate transporter, extracellular lactate from the TME is taken up by the tumor cells. Therefore, MCT-1 overexpression may help tumor cells in the uptake of lactate, which further aids in the process of invasiveness 33 . Glioblastoma multiforme (GBM) is one of the most dangerous types of brain cancer. The glioblastoma cell has the propensity to convert glucose to lactic acid. Through transmembrane transporters known as MCTs, GBMs export lactic acid to the TME to support the survival of neighbouring glioblastoma cells. The authors of this study inhibited the MCT1 transporter using α-cyano-4-hydroxy-cinnamic acid (a small-molecule inhibitor of lactate transport) and studied the effect on the invasiveness of the glioma cell lines U251-MG and U87-MG 34 . Inhibition of the MCT -1 transporter inhibited the invasiveness of brain tumor cells. This research has shown that lactate enhances invasiveness in tumor cells and plays a pivotal role in the aggressive transformation of a solid hypoxic tumor. According to the aforementioned findings, intracellular lactate accumulation in the tumour microenvironment is a crucial metabolite that aids in the activation of several proteolytic enzymes, including MMPs, hyaluronidase-2, and cathepsin B. These proteolytic enzymes dissolve the cell-to-cell adhesion molecules, aiding in the separation of cancer cells from the primary tumour tissue and paving the way for their simple penetration into the tissue of adjacent organs (Figure2). This explains how lactate promotes invasiveness in cancer cells. Lactate also shows a pivotal character in the suppression of antitumor immunity and this is explained in the preceding section . math_shortcuts 4. Lactate acidosis suppresses the anti-tumor immunity in solid hypoxic tumors In addition to stimulating angiogenesis and invasiveness, lactic acidosis also helps cancer cells to escape antitumor immunity. Lactic acid produced by cancer cells has been shown to significantly reduce the cytotoxic activity of natural killer (NK) cells and T lymphocytes, thereby suppressing the immune system’s ability to fight cancer 35 . It has also been noted that lactate inhibits the differentiation of dendritic cells originating from monocytes, and inhibits cytokine secretion from these cells 36 . Studies have also reported the involvement of lactate in the build-up of myeloid-derived suppressor cells, which in turn reduces the activity of T lymphocytes 37 . Additionally, recent research on syngeneic murine tumor models of melanoma cancer cell lines B16-F1 (B16) and Lewis lung carcinoma (LLC) reported the expression of arginase-1 by lactate-induced HIF-1 stabilization, which in turn promoted polarization of tumor-associated macrophages into an M2-like state 38 . Extracellular tumor acidosis has the potential to reduce both immune surveillance and cytolytic action of natural killer (NK) cells and T-lymphocytes and encourage tumor invasion by degrading the extracellular matrix. Consequently, acidosis encourages the migration of tumor cells and has immunosuppressive properties that further aid tumor development 39 . Several studies have reported that tumor cells can escape immunological damage by inhibiting the anti-tumor immune response by maintaining the pH of their microenvironment at a relatively low level. Stephen Yiu Chuen Choi et al. suggested that tumor cells develop an additional mechanism to suppress the antitumor immune response by sustaining a relatively low pH in their microenvironment 40 . Hisani Kanemaru et al, described in their research that lactate can convert hot tumors into cold tumors by suppressing the activity of dendritic cells. To maximize the effectiveness of immune checkpoint inhibitors (ICIs) against malignancies, non-inflamed (cold) tumours must be transformed into inflamed (hot) tumours. They demonstrated that lactate, a byproduct of the Warburg effect, decreased NF-kB p65, p50, and c-Rel DNA-binding activities to the IL-12 p40 promoter, hindered the effectiveness of ICIs, and repressed IL-12 p40 production in dendritic cells (DCs) and in this way hindered the anti-tumor response of dendritic cells 41 . Quin et al, reported that metabolic conditions like high lactate such as in TME pose an immunosuppressive effect on the T cells. As per their finding, NADH is an important regulator in T-cells which is produced when NAD+ is converted to NADH by the lactate dehydrogenase. In lactate rich tumor microenvironment T cells have no reduced NAD+ which is required for activation of NAD+-dependent enzymes 3-phosphoglycerate dehydrogenase (PGDH) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Elevated lactate inhibits GAPDH and PGDH, depleting post-GAPDH glycolytic intermediates and the 3-phosphoglycerate derivative serine, which is crucial for T cell proliferation. Further, they said it might be beneficial to directly target the redox state while creating innovative immunotherapies for cancer and therapeutic immunosuppression 42 . Qiang Feg et al, worked in the same line and demonstrated how lactate can boost anti-tumor immunity by enhancing the stemness of CD8+ T cells. They administered sodium lactate in xenografted mice with Murine melanoma B16F10, colon adenocarcinoma MC38, and TC-1 lung epithelial cells and observed its effect on the immune cells. They noted, CD8+ T reduced the expression of TCF-1 and increased the expression of PD-L1 on their surface. TCF-1 expression has resulted from the inhibition of histone deacetylase activity by lactate accumulation. TCF-1augumeneted stemness in CD8+ T cells and expression of PD-L1 on cancer cells impeded the antitumor effects of immune cells 43 . From the above discussion, it is clear that lactate exploits different pathways in order to suppress the functionality of immune cells. Lactate depletes the availability of GAPDH and PGDH in T cells which are crucial for T-cell proliferation. Lactate modulates the cytotoxic effect of CD8+ cells by enhancing the expression of TGF-1 which help in the development of stemness in CD8+ Tells and enhances the PD-L1 expression on cancer cells (Figure3). math_shortcuts 5. Lactate acidosis enhances fatty acid synthesis in solid hypoxic tumors In the body, lipids play three major roles: as signalling molecules, the storage form of energy, and structural elements of plasma membranes 44 . Every cell’s biological membrane is mostly composed of lipids, such as cholesterol, isoprenoids, acylglycerols, and phospholipids 45 . The capacity of tumor cells to colonize and spread can be aided by an overabundance of lipids. A tumor cell must undergo several phases of metastasis, each of which requires modifications to its metabolic and structural processes involving lipids 46 . Baenke et al. investigated the abnormal role of lipids in the induction of angiogenesis and migration and invasion of cancer cells 47 . Due to these characteristics, cancer cells remain in heavy demand of lipids. Recent studies have also reported that tumor cells can utilize lactate for fatty acid synthesis. Patel et al. investigated how the adipose tissue of fasted and fed rats processed lactate and pyruvate into fatty acids. Several substances, including glucose, propionate, aspartate, butyrate, and pyruvate, induced the transformation of lactate into fatty acids 48 . Another clinical study on cancer patients revealed that in addition to altering glucose metabolism, fatty acids are produced at an extremely high rate in tumor tissues. Experiments using 14C glucose revealed that all fatty acids in tumor cells come from de novo synthesis despite abundant nutritional supply. Furthermore, they reported FASN enzyme involved in the synthesis of de novo fatty acids, is overexpressed in tumors, and this overexpression conferred a selective growth advantage to cancer cells. The study claimed that functions of FASN is crucial in cellular processes, such as apoptosis and cellular proliferation in lactate acidosis and silencing of FASN decreases VEGF expression 49 . In a recent study conducted by Singh et al, reported how Hypoxic cancer cells converted lactate for fatty acid synthesis. Western blotting revealed higher expression of Sterol regulatory elementary binding protein-1c (SREBP-1c) and Fatty acid synthase (FASN) expression in hypoxic cancer cells having higher levels of lactate 50,51 . Ayano et al. reported that an alteration in pHe and pHi in tumor cells results in instability in the endoplasmic protein called Sterol regulatory elemental binding protein-1c (SREBP-1c), which then increases the hyperexpression of enzymes responsible for cholesterol and biosynthesis of other fatty acids 52 . From the above conversation, it is clear that lactate acidosis regulates fatty acid synthesis by activating the SREBP-1c and FASN genes (Figure 4). 6. Curtailment of Lactate acidosis in TME via inhibition of LDH activity can prevent aggressive transformation of cancer From the above discussion, we have understood the multifactorial role of lactate acidosis in the aggressive transformation of solid hypoxic tumors. Curtailment of lactate acidosis could prevent metastatic progression of cancer. Lactate dehydrogenase (LDH) is the main enzyme which oxidise pyruvate into lactate in absence of oxygen. Cancer cells convert pyruvate into lactate even in the presence of oxygen (Warburg effect). Various studies have reported that hypoxic cancer cells over express LDH and subsequently develop lactate acidosis in the tumor microenvironment in order to acquire metastatic behaviour (Table1). Lactate acidosis in hypoxic cancers can be prevented by inhibiting LDH activity. LDH is the primary enzyme in the design and development of innovative anti-cancer therapies. Considering the role of LDH in spread of cancer, various LDH inhibitors have been developed and shown their anti-cancer efficacy in various cancers (Table2). Kim et al. developed selenobenzene compounds as potent LDHA inhibitors. The best effective LDHA inhibitor was 1-(phenylseleno)-4-(trifluoromethyl)benzene (PSTMB), which reduced the enzymatic activity of LDHA to a large extent. Computational modeling and biochemical testing demonstrated that PSTMB suppressed LDHA activity significantly in several tumor cell lines, including MCF-7, NCI-H460, Hep3B, HT29, LLC, and A375. PSTMB also decreased LDHA activity and cell survival in a dose-dependent manner in HT29 human colon tumor cells without altering LDHA expression. In both hypoxic and normoxic environments, PSTMB successfully decreased the lactate synthesis and LDHA activity. Additionally, PSTMB caused HT29 cells to undergo mitochondria-mediated apoptosis through the generation of reactive oxygen species (ROS). This study presented PSTMB as a best LDH inhibitor 53 . In their investigations, Jiayin An et al. demonstrated that invasive pancreatic adenocarcinoma (PA) samples had considerably higher levels of LDHA which enhanced cellular invasion by upregulating MMP-2 and improved glucose absorption by upregulating glucose transporter-1 (Glut1). Further, LDHA regulated the cell cycle through the Akt-GSK-3-cyclinD1 pathway which in turn increased GH3 cell proliferation. At the same time, administration of oxamate, an inhibitor of LDHA, inhibited MMP2 and Glut1 expression, and the Akt-GSK-3-cyclinD1 pathway, which in turn suppressed the invasion, and proliferation in GH3 cells 54 . In this study, oxamate is used as an LDHA inhibitor to combat PA. In another study, the author used FX11 (3-dihydroxy-6-methyl-7-(phenylmethyl)-4-propyl naphthalene-1-carboxylic acid) as an LDHA inhibitor. The results of their study showed that FX11 prevented the spread of lymphoma and pancreatic tumors 55 . A recent review by Sharma et al. classified LDHA inhibitors discovered to date based on their mode of action. Pyruvate competitive inhibitors include oxamate, 3-hydroxy isoxazole-4-carboxylic acid, and 4-hydroxy-1,2,5-thiadiazole-3-carboxylic acid 1-(phenylseleno)-4-(trifluoromethyl)benzene (PSTMB); NADH competitive inhibitors include gossypol, FX11, and (3-((3-(N-cyclopropylsulfamoyl)− 7-(2,4-dimethoxypyrimidin-5-yl)quinolin-4-yl)amino)− 5-(3,5-difluorophenoxy)benzoic acid, which is a Quinoline 3-sulfonamides-based compound; and substrate and co-factor competitive inhibitors include N-hydroxyindoles (NHI) 56 . [56] From the above discussion, it is evident that the chemical inhibition of LDHA could benefit cancer chemotherapy. Clinical and pre-clinical testing of a number of molecules has already reported the importance of LDHA inhibition in solid hypoxic tumors (Table 2). Physicians can prevent the aggressive transformation of cancer cells by inhibiting lactate acidosis through LDHA inhibition (Figure 5). Therefore, researchers should focus on designing small-molecule inhibitors of LDHA. 6.1. LDH isoforms: Their occurrence and function Almost all living cells contain the LDH enzyme. It facilitates the metabolic conversion of lactate into pyruvate, as well as the alteration of NAD+ to NADH, and vice versa 57 . LDH is widely distributed in bodily tissues, including the blood and heart cells. The different isoforms of LDH are shown in Table 1 and are diagrammatically represented in Figure 6 . Studies have reported five basic types of LDHs and all five are made of two subunits i.e Heart (H) and Muscle (M). These are LDH-1 (H4), LDH-2(H3M), LDH-3 (H2M2), LDH-4(HM3) and LDH5(M4) 58 . Recently, LDH-6 also been reported to be present on sperm cells. Genes for subunits of LDH enzymes are located on chromosome 11 and chromosome 12 59 . LDH-5 type of lactate dehydrogenase is consists of four lactate dehydrogenase -A subunits present on muscles, hence also known as LDHA. On the other hand, LDH-1 type lactate dehydrogenase is consists of four lactate dehydrogenase -B subunits present on heart muscles, hence also named as LDHB. Therefore, LDH-1 is also known as LDH-B and LDH-5 is also known as LDH-A. Overexpression of both LDH-A and LDH-B both have been reported in various types of cancerous. LDH-A and LDH-5 have a higher affinity for converting lactate from pyruvate because of subunit M, which has a greater ability to facilitate the reaction. Component H has a strong capacity to reverse the process and transform lactate back into pyruvate 60 . Although the overall processes catalyzed by all five isoforms are similar, each has variable substrate affinities, inhibitory concentrations, isoelectric points, and electrophoretic mobility. These five isoforms can be detected in their active forms using LDH zymography. Cancer and healthy cells respond to LDH in different ways. Tumorous cells use LDH to enhance aerobic metabolism (the Warburg effect). [53] A wide range of tumor tissues, including hematological malignancies and solid tumors such as mesothelioma and thoracic, lung, and pancreatic cancers, have been linked to elevated LDH-A expression 61 . 7. Conclusion It has been established that HIF-1 keeps a careful eye on LDH activity in solid hypoxic cancer cells. With HIF-1’s careful direction, LDH converts pyruvate to lactate, which builds up in the tumour microenvironment and promotes metastasis. If LDH could be blocked, lactate wouldn’t build up and circulate around the tumour as much. In order to effectively target solid hypoxic cancer cells, new LDH inhibitors needed to be developed and synthesized. Several LDH inhibitors are already in clinical trials. Though there are many potential pitfalls that could be overlooked, creating novel LDH inhibitors is rather straightforward. First, researchers need to evaluate the specific isoform of LDH enzymes found in tumour tissue before creating a novel LDH inhibitor. Second, the isoform of LDH must be used to test the affinity and inhibitor potential of the chemical under study. Since the novel chemical may affect the activity of LDH isoforms other than the intended target isoform. Finally, certain medications have been found to be inactive in the acidic tumour microenvironment. The influence of lactic acidosis on the tumour milieu must be properly investigated on the same molecule, rather than just the LDH inhibitory potential. Inhibiting the lactate transporter MCT-1 and & MCT-4 is another strategy for reducing lactate acidosis in the TME. By blocking MCT-1 and MCT-4, lactate can be kept out of the normoxic and hypoxic cancer cells, thereby cutting off their supply. Clinical trials for MCT-1 inhibitors are still very rare. Since MCT-1 and MCT-4 are also expressed in normal tissues. As a result, developing safe new MCT-1/4 inhibitors is a priority. Nanotechnology and liposomes are just two examples of pharmaceutical technologies that can be utilized to deposit medicine in the desired tissue. Since a solid tumor’s pH is typically between 6.5 and 6.8, it falls within this range. With this in mind, tumor-specific nanoparticles and liposomes can be created using pH-sensitive polymers. In addition, while constructing a formulation using nanotechnology, it is crucial to consider medication release and penetration. Lactate acidity in the tumor microenvironment can also be managed with the help of medication combinations. Combinations involving LDHA inhibitors, MCT-1 inhibitors, and HIF-1 inhibitors are possible. While blocking HIF-1 would restrict the production of new LDH enzymes, blocking MCT-1 would stop the circulation of lactate that has already been released. Treatment and management of solid hypoxic tumors will likely soon center on MCT-1 and LDH inhibitors. Declaration of competing interest The authors declare that there are no conflicts of interest Ethics approval Not applicable. Funding Not applicable math_shortcuts CRediT authorship contribution statement Priyanshu Kumar: Writing – original draft. Saumya Rastogi: Figures and tables. Mandeep Kumar Arora: Writing – review & editing, Validation. Lakhveer Singh: Writing – review & editing, Validation, Supervision, Resources, Conceptualization. math_shortcuts Acknowledgment LS and MKA are thankful to the Gurugram University, Gurugram and DIT University, Dehradun where the research work was carried out. Abbreviation: LDH: Lactate dehydrogenase HIF: Hypoxia-inducible factor PI3K: Phosphoinositide 3-kinase MAPK: Mitogen-activated protein kinase NF- κB: Nuclear factor kappa B TME: Tumor microenvironment NK: Natural killer cells MCT: Monocarboxylic acid transporter OXPHOS: Oxidative phosphorylation ATP: Adenosine triphosphate MRP: Multidrug resistance-associated protein TKIs: Tyrosine kinase inhibitors HGF: Hepatocyte growth factor MMR: Miss match repair NSCLC: Non-small-cell lung cancer cAMP: Cyclic Adenosine monophosphate PK: Protein kinase DNA: Deoxyribonucleic acid VEGF: Vascular epithelial growth factor IL: Interleukin ICH: Intracerebral hemorrhage mRNA: messenger Ribonucleic acid bFGF: basic fibroblast growth factor TGF-β: Transforming growth factor-β SDF: Stromal cell-derived factor ECM: Extracellular matrix MMP: Matrix metalloproteinase s FGF: Fibroblast proliferation factor GBM: Glioblastoma multiforme LLC: Lewis lung carcinoma EIT: Epithelial immune-cell transition ICI: Immune checkpoint inhibitor DC: Dendritic cells SRF: Serum response factor PGDH: Phosphoglycerate dehydrogenase GAPDH: Glyceraldehyde 3-phosphate dehydrogenase FABP: Fatty acid-binding proteins ROS: Reactive oxygen species TCA: Tricarboxylic acid FA: Fatty acid SREBP: Sterol regulatory elemental binding protein SRE: Sterol response element GLUT: Glucose Transporter mTOR: Mammalian Target of Rapamycin L-2HG: L-2-hydroxyglutarate MDH: Malate dehydrogenases β-HB: β-hydroxybutyrate PSTMB: 1-(phenylseleno)-4-(trifluoromethyl)benzene PA: Pancreatic adenocarcinoma NHI: N-hydroxyindoles

1. Corbet, C. & Feron, O. Tumour acidosis: From the passenger to the driver’s seat. Nature Reviews Cancer vol. 17 577–593 at https://doi.org/10.1038/nrc.2017.77 (2017).2. Wu, H., Ying, M. & Hu, X. Lactic acidosis switches cancer cells from aerobic glycolysis back to dominant oxidative phosphorylation. Oncotarget 7, 40621–40629 (2016).3. Gao, J. et al. Differential metabolic responses in breast cancer cell lines to acidosis and lactic acidosis revealed by stable isotope assisted metabolomics. Sci. Rep. 10, 1–12 (2020).4. Chen, J. L. Y. et al. The genomic analysis of lactic acidosis and acidosis response in human cancers. PLoS Genet. 4, (2008).5. Zanza, C. et al. Lactic Acidosis Related to Pharmacotherapy and Human Diseases. Pharmaceuticals 15, 1–15 (2022).6. Chen, Z., Han, F., Du, Y., Shi, H. & Zhou, W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct. Target. Ther. 8, (2023).7. Pérez-Tomás, R. & Pérez-Guillen, I. Lactate in the Tumor Microenvironment : An Essential. 1–29 (2020).8. Rastogi, S. et al. Lactate acidosis and simultaneous recruitment of TGF-β leads to alter plasticity of hypoxic cancer cells in tumor microenvironment. Pharmacol. Ther. 250, 108519 (2023).9. Heneberg, P. Lactic Acidosis in Patients with Solid Cancer. Antioxid Redox Signal . 37, 1130–1152 (2021).10. Fischbeck, A. J. et al. Tumor Lactic Acidosis: Protecting Tumor by Inhibiting Cytotoxic Activity Through Motility Arrest and Bioenergetic Silencing. Front. Oncol. 10, 1–14 (2020).11. Chen, J. L. Y. et al. Lactic acidosis triggers starvation response with paradoxical induction of TXNIP through MondoA. PLoS Genet. 6, (2010).12. Ishihara, S. et al. The lactate sensor GPR81 regulates glycolysis and tumor growth of breast cancer. Sci. Rep. 12, 1–14 (2022).13. Hompland, T., Fjeldbo, C. S. & Lyng, H. Tumor hypoxia as a barrier in cancer therapy: Why levels matter. Cancers (Basel). 13, 1–23 (2021).14. Maeda, H. & Khatami, M. Analyses of repeated failures in cancer therapy for solid tumors: poor tumor‐selective drug delivery, low therapeutic efficacy and unsustainable costs. Clin. Transl. Med. 7, 1–20 (2018).15. Muz, B., de la Puente, P., Azab, F. & Azab, A. K. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia 83 (2015) doi:10.2147/hp.s93413.16. Yang, C., Pan, R.-Y., Guan, F. & Yuan, Z. Lactate metabolism in neurodegenerative diseases. Neural Regen. Res. 19, 69–74 (2024).17. Barnes, E. M. E. et al. Lactic acidosis induces resistance to the pan-Akt inhibitor uprosertib in colon cancer cells. Br. J. Cancer 122, 1298–1308 (2020).18. Apicella, M. et al. Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies. Cell Metab. 28, 848-865.e6 (2018).19. Qu, J. et al. C. Tropicalis promotes chemotherapy resistance in colon cancer through increasing lactate production to regulate the mismatch repair system. Int. J. Biol. Sci. 17, 2756–2769 (2021).20. Ma, R. et al. Dual Roles of Lactate in EGFR-TKI-Resistant Lung Cancer by Targeting GPR81 and MCT1. J. Oncol. 2022, (2022).21. Nishida, N., Yano, H., Nishida, T., Kamura, T. & Kojiro, M. Angiogenesis in cancer. Vasc. Health Risk Manag. 2, 213–219 (2006).22. Sonveaux, P. et al. Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PLoS One 7, (2012).23. Végran, F., Boidot, R., Michiels, C., Sonveaux, P. & Feron, O. Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-kB/IL-8 pathway that drives tumor angiogenesis. Cancer Res. 71, 2550–2560 (2011).24. Zhou, J. et al. Lactate potentiates angiogenesis and neurogenesis in experimental intracerebral hemorrhage. Exp. Mol. Med. 50, (2018).25. Dhup, S., Dadhich, R. K., Porporato, P. E. & Sonveaux, P. . 1319–1330 (2012).26. Hunt, T. K., Aslam, R., Hussain, Z. & Beckert, S. Lactate, with oxygen, incites angiogenesis. Adv. Exp. Med. Biol. 614, 73–80 (2008).27. Liu, Q. et al. A Fenton reaction at the endoplasmic reticulum is involved in the redox control of hypoxia-inducible gene expression. Proc. Natl. Acad. Sci. U. S. A. 101, 4302–4307 (2004).28. Altorki, N. K. et al. Global evolution of the tumor microenvironment associated with progression from preinvasive invasive to invasive human lung adenocarcinoma. Cell Rep. 39, 110639 (2022).29. Baro, L., Almhassneh, R. A., Islam, A. & Juanes, M. A. Tumor invasiveness is regulated by the concerted function of APC, formins, and Arp2/3 complex. iScience 27, 109687 (2024).30. Riemann, A. et al. Extracellular Acidosis Modulates the Expression of Epithelial-Mesenchymal Transition (EMT) Markers and Adhesion of Epithelial and Tumor Cells. Neoplasia (United States) 21, 450–458 (2019).31. Ji, K., Mayernik, L., Moin, K. & Sloane, B. F. Acidosis and proteolysis in the tumor microenvironment. Cancer Metastasis Rev. 38, 103–112 (2019).32. Pennington, Z. et al. Lactate and cancer: spinal metastases and potential therapeutic targets (part 2). Ann. Transl. Med. 7, 221–221 (2019).33. Izumi, H. et al. Monocarboxylate transporters 1 and 4 are involved in the invasion activity of human lung cancer cells. Cancer Sci. 102, 1007–1013 (2011).34. Colen, C. B. et al. Metabolic targeting of lactate efflux by malignant glioma inhibits invasiveness and induces necrosis: An in vivo study1. Neoplasia 13, 620–632 (2011).35. Certo, M., Tsai, C. H., Pucino, V., Ho, P. C. & Mauro, C. Lactate modulation of immune responses in inflammatory versus tumour microenvironments. Nat. Rev. Immunol. 21, 151–161 (2021).36. Manoharan, I., Prasad, P. D., Thangaraju, M. & Manicassamy, S. Lactate-Dependent Regulation of Immune Responses by Dendritic Cells and Macrophages. Front. Immunol. 12, 1–15 (2021).37. Li, Y. et al. Novel Characterization of Myeloid-Derived Suppressor Cells in Tumor Microenvironment. Front. Cell Dev. Biol. 9, 1–15 (2021).38. Marchiq, I. & Pouysségur, J. Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H+ symporters. J. Mol. Med. 94, 155–171 (2016).39. Chiche, J., Brahimi-Horn, M. C. & Pouysségur, J. Tumour hypoxia induces a metabolic shift causing acidosis: A common feature in cancer. J. Cell. Mol. Med. 14, 771–794 (2010).40. Choi, S. Y. C., Collins, C. C., Gout, P. W. & Wang, Y. Cancer-generated lactic acid: A regulatory, immunosuppressive metabolite? J. Pathol. 230, 350–355 (2013).41. Kanemaru, H. et al. A mechanism of cooling hot tumors: Lactate attenuates inflammation in dendritic cells. iScience 24, 103067 (2021).42. Iii, W. J. Q. et al. HHS Public Access. 33, (2021).43. Feng, Q. et al. Lactate increases stemness of CD8 + T cells to augment anti-tumor immunity. Nat. Commun. 13, (2022).44. Szlasa, W., Zendran, I., Zalesińska, A., Tarek, M. & Kulbacka, J. Lipid composition of the cancer cell membrane. J. Bioenerg. Biomembr. 52, 321–342 (2020).45. Harayama, T. & Riezman, H. Understanding the diversity of membrane lipid composition. Nat. Rev. Mol. Cell Biol. 19, 281–296 (2018).46. Fu, Y. et al. Lipid metabolism in cancer progression and therapeutic strategies. MedComm 2, 27–59 (2021).47. Baenke, F., Peck, B., Miess, H. & Schulze, A. Hooked on fat: The role of lipid synthesis in cancer metabolism and tumour development. DMM Dis. Model. Mech. 6, 1353–1363 (2013).48. Patel Mulchand S., † N. S., D., W. I. & S., K. D. Gene Regulation and Genetic Defects in the Pyruvate Dehydrogenase Complex. J. Nutr. 125, 1753S-1757S (1995).49. Baron, A., Migita, T., Tang, D. & Loda, M. Fatty acid synthase: A metabolic oncogene in prostate cancer? J. Cell. Biochem. 91, 47–53 (2004).50. Singh, L. et al. Repurposing Combination Therapy of Voacamine With Vincristine for Downregulation of Hypoxia-Inducible Factor-1α/Fatty Acid Synthase Co-axis and Prolyl Hydroxylase-2 Activation in ER+ Mammary Neoplasia. Front. Cell Dev. Biol. 9, 1–19 (2021).51. Singh, L. et al. Effect of Voacamine upon inhibition of hypoxia induced fatty acid synthesis in a rat model of methyln-nitrosourea induced mammary gland carcinoma. BMC Mol. Cell Biol. 22, 1–17 (2021).52. Kondo, A. et al. Extracellular Acidic pH Activates the Sterol Regulatory Element-Binding Protein 2 to Promote Tumor Progression. Cell Rep. 18, 2228–2242 (2017).53. Kim, E. Y. et al. A Novel Lactate Dehydrogenase Inhibitor, 1-(Phenylseleno)-4-(Trifluoromethyl) Benzene, Suppresses Tumor Growth through Apoptotic Cell Death. Sci. Rep. 9, 1–12 (2019).54. An, J. et al. Lactate dehydrogenase A promotes the invasion and proliferation of pituitary adenoma. Sci. Rep. 7, 1–12 (2017).55. Le, A. et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc. Natl. Acad. Sci. U. S. A. 107, 2037–2042 (2010).56. Dolly Sharma, Singh, M. & Rani, R. Role of LDH in tumor glycolysis: Regulation of LDHA by small molecules for cancer therapeutics. Semin. Cancer Biol. 87, 184–195 (2022).57. Goodwin, M. L., Gladden, L. B., Nijsten, M. W. N. & Jones, K. B. Lactate and Cancer: Revisiting the Warburg Effect in an Era of Lactate Shuttling. Front. Nutr. 1, 2014–2016 (2015).58. Głowacka-Gudanek, J., Gryckiewicz, K. & Strzelak, K. Analytical approach to distinguishing lactate dehydrogenase fractions for oncological diagnostics. Anal. Chim. Acta 1352, 343921 (2025).59. Koudelová, J., Rauchová, H. & Vokurková, M. Activity of lactate dehydrogenase in serum and cerebral cortex of immature and mature rats after hypobaric hypoxia. Neurochem. Res. 31, 915–919 (2006).60. Claps, G. et al. The multiple roles of LDH in cancer. Nat. Rev. Clin. Oncol. 19, 749–762 (2022).61. Comandatore, A. et al. Lactate Dehydrogenase and its clinical significance in pancreatic and thoracic cancers. Semin. Cancer Biol. 86, 93–100 (2022). Figure legends Figure 1: Lactate acidosis induces angiogenesis in hypoxic cancer tumors. Highly dependent on glucose, solid hypoxic cancer cells metabolize glucose through glycolysis, and the end-product pyruvate is converted into lactate-by-lactate Dehydrogenase A (LDHA). Excess lactate produced intracellularly is pumped out of the tumor microenvironment through the MCT-4 transporter. Cancer-associated fibroblasts (CAF) also metabolize glucose through the same route and further increase lactate acidosis in the tumor microenvironment. Normoxic cancer cells (near blood vessels) are less dependent on glucose, but also synthesize and secrete lactate, which further aids tumor acidity. Accumulated lactate initiates angiogenesis, both directly and indirectly. In the direct mechanism, lactate from the tumor microenvironment circulates toward the nearby blood vessels and then acts on endothelial cells as a signaling molecule for the initiation of angiogenesis. To initiate angiogenesis indirectly, lactate first enters macrophages, thereby enhancing the expression of vascular endothelial growth factors (VEGFs), Arginase-1(Arg1), and Retnla. In addition to assisting in the anti-inflammatory process, VEGFs), Arginase-1(Arg1), and Retnla act on specific receptors on endothelial cells and subsequently activate the differentiation of endothelial cells into tip and stalk cells. Along with this, lactate acidosis forces the different types of cells in the tumor microenvironment to release VEGF, metalloproteinases (MMPs), and various growth factors such as fibroblast growth factor(FGF) and epithelial growth factor (EGF), Transforming growth factor-β(TGF-β) which further help solid hypoxic tumor cells to develop new blood vessels. Lactate enters normoxic tumor cells via the reverse Warburg effect to increase ROS production, which also has a role in the induction of angiogenesis but the exact mechanism is still remains unexplored. Figure 2: Lactate acidosis promotes invasiveness in hypoxic tumors. math_shortcuts Accumulated lactate acidosis resulting from aerobic and anaerobic glucose metabolism in the tumor microenvironment activates collagen matrix metalloproteinases (MMPs), tumor growth factor-β(TGF-β), fibroblast growth factor (FGF), and epithelial growth factor (EGFG). MMPs break down the N -N-cadherin and vimentin, which help in the detachment of cancer cells from the primary tumor site. Lactate acidosis also enhances the production of various cytokines such as TGF-β and growth factors such as FGF and EGF, which causes blood vessels to leak and subsequently helps in intravasation, dissemination, and extravasation of tumor cells to distance regions. Once in circulation, tumor cells disseminate to the brain, liver, lungs, and kidney tissues. Through extravasation, tumor cells invade the parenchymatous tissue of the lungs, liver, brain, and kidneys. N-cadherin and Vimentin re-establish a link between adjacent tumor cells, and eventually, secondary tumors develop in the target organs. This is how lactate assists in the invasiveness. Figure 3: Lactate acidosis impairs the function immune cells in hypoxic tumors. Hypoxia-induced lactate acidosis in the TME plays a pivotal role in suppressing the immune function of immune cells. Extracellular lactate suppresses their differentiation into M2 types macrophages. Dendritic cells fail to express the antigens in presence of lactate acidosis. Similarly, cytotoxic T cells decrease intracellular pH due to the increased expression of lactate, which acts as a histone deacetylate (HDAC) inhibitor, triggering the Tcf-7 transcription factor, which enables T cell stemness. Figure 4: Lactate acidosis promotes fatty acid synthesis in hypoxic tumors. Glucose in hypoxic tumor cells oxidized to anaerobically and end product lactate is pumped out in the tumor microenvironment (TME). Lactate from TME taken up by the nearby cancer cells and eventually alter the pHi and pHe tumor cells. This develops a proton gradient across the plasma mebrane of cancer cells which further activates the transcription factor sterol regulatory element-binding protein-1c (SREBP-1c) from endoplasmic reticulum and enters the nucleus. SREBP-1c further enhances the expression of FANS which converts citrate into fatty acid. Extra fatty acid is stored as lipid droplets in the hypoxic cancer cells to meet energy demands in future. Lactate from TME is also enters the normoxic cancer cells through MCT-1 transporter converted back into pyruvate which is rapidly converted into citrate. Citarte is further incorporated into fatty acids and extra fatty acid synthesized in way uutilized in cell mebrane synthesis as well as oxidized in mitochondria by β-oxidation. Lipid drops from hypoxic cancer cells are also shared and used in normoxic cancer cells and vice-versa. Therefore, lactate helps in developing metabolic symbiosis in cancer cells in TME. Figure5: Lactate dehydrogenase-A promising target to block aggressive transformation of hypoxic tumors In solid hypoxic cancer cells, hypoxia-inducible factor-1α (HIF-1α) activates the genes for lactate dehydrogenase, which converts glucose to lactic acid (Warburg effect). Continuous synthesis of lactate is then pumped out in the extracellular region, making the tumor microenvironment acidic. Hypoxia-induced lactate acidosis further benefits cancer by promoting aggressive transformation, enhancing angiogenesis and invasiveness, developing resistance to chemotherapy, and suppressing the anti-cancer immune response. The aggressive transformation of solid hypoxic cancer cells can be prevented by inhibiting lactate acidosis, which can be blocked by inhibiting Lactate Dehydrogenase A (LDHA) and (LDHB) Figure 6: Structural representation of different isoforms of Lactate dehydrogenases with reaction-catalyzed All LDH enzymes are consists of 4 homo and hetero tetrameric subunits. LDHA (also known as LDH 5) consists of 4 identical M (Skeletal muscle) subunits and LDHB (also known as LDH 1) consists of 4 identical H (heart) units. LDH2,3 and 5 consists of 4 different subunits. Lactate dehydrogenases A and B are both cytoplasmic enzymes. LDHA converts pyruvate to lactate, whereas LDHB transforms lactate back into pyruvate. Information & Authors Information Version history Copyright This work is licensed under a Non Exclusive No Reuse License.

Authors Metrics & Citations Metrics Article Usage 262views 107downloads Citations Download citation Priyanshu Kumar, Saumya Rastogi, Mandeep Kumar Arora, et al. The inclusion of lactate dehydrogenase and the resulting lactic acidosis play a role in the transformation of solid hypoxic cancers into metastatic tumour's.. Authorea. 23 June 2025. DOI: https://doi.org/10.22541/au.175068199.94843243/v1 DOI: https://doi.org/10.22541/au.175068199.94843243/v1 If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download. For more information or tips please see 'Downloading to a citation manager' in the Help menu.